Related Experiment Video
Updated: May 14, 2026
06:52
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Drug development status for Alzheimer's disease: present scenario
1Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
Summary
Developing effective Alzheimer's disease treatments requires reconsidering drug development strategies. Focusing on pharmacological interactions, rather than single targets, may yield better therapeutic approaches for Alzheimer's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Development
Background:
- Alzheimer's disease (AD) research has yielded symptomatic treatments but few disease-modifying therapies.
- Successes and failures in AD drug development prompt re-evaluation of pathogenesis understanding and therapeutic strategies.
- Current approaches face challenges in diagnosis, target selection, drug candidate development, and clinical trial design.
Purpose of the Study:
- To analyze the successes and failures in Alzheimer's disease therapy development.
- To discuss potential deficiencies in understanding AD pathogenesis and therapeutic development pitfalls.
- To propose a reconsideration of the drug development approach for Alzheimer's disease.
Main Methods:
- Review of recent advances in Alzheimer's disease pathogenesis research.
- Analysis of clinical and experimental studies on Alzheimer's disease therapies.
- Examination of ongoing randomized controlled trials (RCTs) in Alzheimer's disease.
Main Results:
- Symptomatic treatments for Alzheimer's disease have seen some success, while disease-modifying therapies have faced numerous failures.
- Deficiencies may exist in understanding AD pathogenesis, diagnosis, target selection, drug development, and clinical trial design.
- Preclinical research suggests focusing on patterns of pharmacological interactions may be more fruitful than targeting single molecules.
Conclusions:
- A single cure for Alzheimer's disease is unlikely; a revised drug development approach is necessary.
- Future Alzheimer's disease drug development should consider complex pharmacological interactions.
- Increased collaboration among pharmaceutical companies, basic researchers, and clinical researchers is crucial for optimal therapeutic strategies.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...